The Future is Now: Oncology Pharmacogenetics and Pharmacogenomics Reach the Bedside

Davis, R.E. and L.M. Staudt (2002). “Molecular Diagnosis of Lymphoid Malignancies by Gene Expression Profiling.” Curr Opin Hematol 9: 333— 8.

Ingelman-Sundberg, M. (2001). “Genetic Susceptibility to Adverse Effects of Drugs and Environmental Toxicants. The Role of the CYP Family of Enzymes.” Mutat Res 482: 11—19.

Los, G. et al. (2002). “Using mRNA Expression Profiling to Determine Anticancer Drug Efficacy.” Cytometry 47: 66—71.

Ramaswamy, S. and T.R. Golub (2002). “DNA Microarrays in Clinical Oncology. ” J Clin Oncol 20: 1932—41.

Relling, M.V. , and Dervieux, T. (2001). “Pharmacogenetics and Cancer Therapy. ” Nature Rev Cancer 1: 99—108.

Roses, A.D. (2001). “Pharmacogenetics.” Hum Mol Genet 10: 2261—7.

Schena, M. , D. Shalon , R.W. Davis , et al. (1995). “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray.” Science 270: 467—70.

Slonim, D.K. (2001). “Transcriptional Profiling in Cancer: The Path to Clinical Pharmacogenomics.” Pharmacogenomics 2: 123—36.

Taylor, J.G. et al. (2001). “Using Genetic Variation to Study Human Disease.” Trends Mol Med 7: 507—12.

van de Vijver, M.J. , Y.D. He , L.J. van't Veer , et al. (2002). “A Gene-Expression Signature as a Predictor of Survival in Breast Cancer.” N Engl J Med 347: 1999—2009.

Weber, W. , J. Estoppey , and H. Stoll (2001). “Familial Cancer Diagnosis. ” Anticancer Res 21: 3631.

Weinstein, J.N. (2000). “Pharmacogenomics—Teaching Old Drugs New Tricks.” N Engl J Med 343: 1408—9.

Zanders, E.D. (2000). “Gene Expression Analysis as an Aid to the Identification of Drug Targets. Pharmacogenomics 1: 375—84.